The Belfer family, led by oil tycoon Robert Belfer, had donated an additional $20 million to the Belfer Neurodegeneration Consortium. Photo via mdanderson.org

Neurodegeneration is one of the cruelest ways to age, but one recent donation is invigorating research with the goal of eradicating diseases like Alzheimer’s.

This month, Laurence Belfer announced that his family, led by oil tycoon Robert Belfer, had donated an additional $20 million to the Belfer Neurodegeneration Consortium, a multi-institutional initiative that targets the study and treatment of Alzheimer’s disease.

This latest sum brings the family’s donations to BNDC to $53.5 million over a little more than a decade. The Belfer family’s recent donation will be matched by institutional philanthropic efforts, meaning BNDC will actually be $40 million richer.

BNDC was formed in 2012 to help scientists gain stronger awareness of neurodegenerative disease biology and its potential treatments. It incorporates not only The University of Texas MD Anderson Cancer Center, but also Baylor College of Medicine, Massachusetts Institute of Technology (MIT) and Icahn School of Medicine at Mount Sinai.

It is the BNDC’s lofty objective to develop five new drugs for Alzheimer’s disease and related disorders over the next 10 years, with two treatments to demonstrate clinical efficacy.

“Our goal is ambitious, but having access to the vast clinical trial expertise at MD Anderson ensures our therapeutics can improve the lives of patients everywhere,” BNDC Executive Director Jim Ray says in a press release. “The key elements for success are in place: a powerful research model, a winning collaborative team and a robust translational pipeline, all in the right place at the right time.”

It may seem out of place that this research is happening at MD Anderson, but scientists are delving into the intersection between cancer and neurological disease through the hospital’s Cancer Neuroscience Program.

“Since the consortium was formed, we have made tremendous progress in our understanding of the molecular and genetic basis of neurodegenerative diseases and in translating those findings into effective targeted drugs and diagnostics for patients,” Ray continues. “Yet, we still have more work to do. Alzheimer's disease is already the most expensive disease in the United States. As our population continues to age, addressing quality-of-life issues and other challenges of treating and living with age-associated diseases must become a priority.”

And for the magnanimous Belfer family, it already is.

At Rezvani Lab in MD Anderson Cancer Center, scientists train immune cells to fight cancer. Photo via Getty Images

Unique cell therapy developed in Houston doses inaugural patient

cancer-fighting innovation

Replay, a genome-writing company headquartered in San Diego, has announced that its first patient has been dosed with an engineered T-Cell Receptor Natural Killer (TCR-NK) cell therapy for relapsed or refractory multiple myeloma.

What does that have to do with Houston? Last year, Replay incorporated a first-in-class engineered TCR-NK cell therapy product company, Syena, using technology developed by Dr. Katy Rezvani at The University of Texas MD Anderson Cancer Center.

Rezvani, a professor of stem cell transplantation and cellular therapy, is the force behind MD Anderson’s Rezvani Lab, a group of 55 people, all focused on harnessing natural killer cells to combat cancer.

“Everybody thinks that the immune system is fighting viruses and infections, but I feel our immune system is capable of recognizing and killing abnormal cells or cells that are becoming cancerous and they're very powerful. This whole field of immunotherapy really refers to the power of the immune system,” Rezvani tells InnovationMap.

Dr. Katy Rezvani is a professor of stem cell transplantation and cellular therapy and the force behind MD Anderson’s Rezvani Lab, which is focused on harnessing natural killer cells to combat cancer. Photo via mdanderson.org

At Rezvani Lab, scientists train immune cells to fight cancer. While cancer drugs like chemotherapy are still the norm, immunotherapy has gained ground, led by Houston research, including the work of Nobel laureate Jim Allison. The harnessed cells are taught to attack cancerous cells, while ignoring healthy ones, says Rezvani. “We’re turning them into heat-seeking missiles,” she explains.

However, there must be a beacon to signal to those “missiles” that there is something to attack. Much of the field has used chimeric antigen receptors (CARs) to achieve that. But they have limitations.

“CARs can only recognize beacons that sit on the surface of the tumor cells,” Rezvani says. “So basically, it's like the tumor cell has to have a hat on it.”

She says that this usually means that the targets that send off a signal are relatively limited, mostly blood cancers. Using T cell receptors (TCRs) may be able to open up the field to look beyond the “hat.” In other words, TCRs can peer inside cells and see what differentiates a tumor cell from healthy cells. With Replay, Rezvani Lab has developed a first-in-class and first-in-human approach of engineering natural killer cells to express the TCR.

There are six different FDA-approved products that use CAR-T cells, but Rezvani says that her TCR-NK-based technology, though still in its early phases, shows great promise.

“We could use it to target many different types of antigens, many different types of cancers, especially solid tumors," she explains. "These cell therapies have a lot of potential — we call them living drugs… It's not like chemotherapy where you have to keep giving different multiple cycles, these cells are very long lived.”

Rezvani, who started her career in London, says that Houston has been instrumental in the success of her lab.

“There are so many opportunities because we have access to some of the most brilliant minds in research,” Rezvani says. “We have some of the best clinicians in the world. We have patients who come to us who are willing to participate in our clinical trials — really put their trust in us — and are committed and want to participate in these clinical studies.”

The role of funding also plays a part. As Rezvani admitted, bringing a new technology to the market is expensive. The philanthropists who help support trials can’t be forgotten among Houston’s finest.

Whether or not Syena produces the first TCR-NK product on the market, Rezvani is enthusiastic and hopeful for the future of her patients.

“The field of immunotherapy is really expanding, the field of cell therapies is expanding, and there is so much promise,” she says. “The promise of AI, big data, all the engineering tools that we have available, the promise of CRISPR — all of that is going to bring what we've learned from biology, from basic science, together to help us make the cell therapies that are going to be safe and and also very effective for our patients.”

MD Anderson’s goal with the new Institute for Data Science in Oncology is to advance collaborative projects that will bring the power of data science to every decision made at the hospital. Photo via mdanderson.org

Houston organization introduces inaugural cancer-fighting cohort of data sciences, experts

new to hou

The University of Texas MD Anderson Cancer Center is one step closer to ending cancer thanks to its new institute that's focused on data science.

MD Anderson’s goal with the new Institute for Data Science in Oncology (IDSO) is to advance collaborative projects that will bring the power of data science to every decision made at the hospital. And now, the IDSO has announced its inaugural cohort of 33 scientists, clinicians, and staff that will bring it to life, joining the already appointed leadership and focus area co-leads.

“By engaging diverse expertise across all of our mission areas, we will enhance the rich and productive data science ecosystem at MD Anderson to deliver transformational impact for patients,” David Jaffray, Ph.D., director of IDSO and chief technology and digital officer at MD Anderson, says in a press release.

The focus areas for the IDSO are quantitative pathology and medical imaging; single-cell analytics; computational modeling for precision medicine; decision analytics for health; and safety, quality, and access.

The IDSO Affiliates, as they are known, are a mix of existing contributors to the IDSO and team members who were recruited specifically for their expertise in data science. The affiliates were chosen to fulfill a two-year term, during which they will focus on IDSO projects related to the focus areas above. The diverse roster of professionals includes:

“Our affiliates bring expertise, perspectives and commitment from across the institution to foster impactful data science in order to tackle the most urgent needs of our patients and their families,” said Caroline Chung, M.D., director of Data Science Development and Implementation for IDSO and chief data officer at MD Anderson. “People and community are at the heart of our efforts, and establishing the IDSO Affiliates is an exciting step in growing the most impactful ecosystem for data science in the world.”

MD Anderson broke ground on a 600,000 square-foot building that is specifically designed to enable great minds to meet with the goal of conquering cancer. Photo courtesy of MD Anderson

Houston-based, cancer-fighting organization breaks ground on new collaborative building

ready to rise

Houston is where medical researchers and clinicians come together. And it’s getting easier for that to happen thanks to an innovative new facility from The University of Texas MD Anderson Cancer Center.

On September 20, the world-class institution broke ground on a 600,000 square-foot building that is specifically designed to enable great minds to meet with the goal of conquering cancer.

Construction on the seven-story structure, known as South Campus Research Building 5 (SCRB5), is supported by a $668 million institutional grant. The facility is expected to be completed in 2026. Designed by Elkus Manfredi Architects, it will include both high-tech research rooms and public spaces that include a restaurant, conference center and spaces for lectures. A landscaped park is designed by Mikyoung Kim Design.

“The construction of our visionary new research building marks the beginning of our next chapter in Making Cancer History,” Peter WT Pisters, M.D., president of MD Anderson, says in a press release. “With input from hundreds of MD Anderson teammates, we have carefully designed this building and our research campus to foster collaboration, to stimulate creativity and to fuel breakthroughs that will improve the lives of patients here and around the globe.”

SCRB5 is located at 1920 Spanish Trail and is considered an extension of upcoming Helix Park, Texas Medical Center’s 5 million square-foot research campus. Both are specifically designed to create seamless collaborations between scientists and clinicians, where water cooler chat can lead to world-changing discoveries. MD Anderson has already announced that the building will be home to a number of strategic research programs, including the James P. Allison Institute.

The new construction isn’t just notable for the discoveries that will be made there. In itself, SCRB5 will be an exceptionally sustainable and efficient building, with surrounding green spots and connecting pathways that will serve as inspiration for all who work there. This only makes sense for MD Anderson, which invested $1.1 billion in funding in the last fiscal year. In the same year, the institution had more projects funded by the National Cancer Institute than any other.

Rendering courtesy of MD Anderson

Houston-based MD Anderson will help the University of Texas expand its medical school in Austin. University of Texas at Austin/Facebook

MD Anderson, UT team up to expand medical school

ready to grow

Powerhouse and award-winning Houston cancer center MD Anderson will partner with the University of Texas at Austin to expand Dell Medical School and build two new hospitals.

This new medical center, called The University of Texas at Austin Medical Center, will include two facilities: a comprehensive cancer center operated by MD Anderson and a multi-specialty hospital operated by the University of Texas.

The project will be made possible by the demolition of the 500,000-square-foot Frank Erwin Center, which officially closed in May 2022. Its replacement, the Moody Center, officially opened to the public in April 2022, and in April 2023 celebrated its jam-packed first year.

In May, the UT System's Board of Regents approved an item paving the way for Dell Medical School's expansion. The full demolition is estimated to cost $25 million, and the university hopes to finish the demolition project by October 2024.

University Chancellor James Milliken and Board of Regents Chair Kevin Eltife announced the project on Monday along with Gov. Greg Abbott.

MD Anderson is a branch of the UT system and was recently named No. 1 in the country for cancer care by U.S. News & World Report. It is the largest cancer care center in the U.S. and one of the original three comprehensive cancer centers in the country.

--

An earlier version of this story reported one new facility instead of two. It has been updated to reflect the correct information. Read the full story and watch the video at KVUE.com.

MD Anderson has tapped an innovative new company to improve the efficacy of cancer treatments. Photo via mdanderson.org

Houston hospital launches partnership with venture-backed therapeutics startup

green light

The sad reality is that not every cancer responds to medication, but a new collaboration is taking steps to close the gaps for scores of patients who were previously left without a clear solution.

The University of Texas MD Anderson Cancer Center and Nexo Therapeutics announced last week that they are collaborating, a move that could lead to the discovery of therapies that could work for patients with limited treatment options.

The Colorado- and Massachusetts-based company joins forces with Houston’s cancer-fighting powerhouse after emerging from stealth with a $60 million series A.

“For many cancer patients, there are no therapies that target the fundamental drivers of their disease,” says Nexo’s founder and CEO, Andrew Phillips, in a press release. He goes on to say that the company’s innovations in covalent chemistry and chemical biology, along with cancer biology and medical chemistry allows it to advance novel therapies.

But in order to get the drugs that Nexo creates onto the market, it is taking advantage of MD Anderson’s first-rate translational research and expertise in drug development. Specifically, Nexo will work with MD Anderson’s TRACTION (Translational Research to AdvanCe Therapeutics and Innovation in ONcology) platform. The pairing will allow the two bodies to accelerate the development of small-molecule therapies through drug-enabling studies.

“Together with Nexo’s innovative platform, our integrated approach to translational research and drug development is poised to design and rapidly advance novel therapies against high priority oncology targets,” says Tim Heffernan vice president of Oncology Research for TRACTION at MD Anderson, in a press release. “This collaboration highlights our commitment to advancing innovative new medicines that address critical unmet needs for our patients.”

TRACTION is part of MD Anderson’s Therapeutics Discovery Division. It combines a team of doctors, researchers, and drug development specialists to bring therapies from discovery to clinical trials. TRACTION researchers will work with Nexo to identify cancers that might be susceptible to their treatments, then find strategies to target them, and finally use biomarkers to help optimize patient selection.

Nexo will help to provide funding to support this research and will retain rights to programs under the collaboration, and will take sole responsibility for development, manufacturing, and commercialization. Meanwhile, MD Anderson may receive royalties and future payments based on milestones as they are obtained. But the real reward will be treating patients who were previously low on options.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

New app with tips for solo women travelers takes flight from Texas

explore mode activated

We all have that one friend whose office seems to be the nearest airport gate. We go to them for travel advice and hit save on their latest post for that hole-in-the-wall restaurant that had the best local food. That type of advice — especially between women — is indispensable for solo travelers, and now a new travel app based in Austin is helping organize it on a new platform without the social media noise.

Solo travel has gained a lot of momentum in the past few years, and it’s no longer just something one does during a gap year before or after college. It’s become the preferred way to travel for many, and women are at the forefront.

According to Condor Ferries, 72 percent of American women like to take solo trips, and the term “female solo travel” has increased 62 percent over the past three years across all search engines. What if there was a place where women solo travelers could get recommendations and travel itineraries created by other solo women travelers?

This concept is the backbone of Airheart, which aims to revolutionize the travel industry by offering a safe space for solo female travelers to find itineraries and travel guides that were crafted with them in mind.

"Traveling solo as a woman is an empowering act of independence," said Airheart founder Lindsey Renken in a press release. "At Airheart, we celebrate and support this journey, helping women discover new places, connections, and strengths."

The platform includes integrated planning tools, interactive maps, itineraries, and video tips all conveniently located in one place and customizable to the traveler’s preference. Once a user creates an account and accesses the site, the navigation is pretty straightforward.

There’s an explore option at the top of the home screen showcasing all the travel guides available for purchase within the platform, with destinations all over the world. At the moment, most are within the US, Mexico, Western Europe, and Asia. Once the user chooses a guide, a sidebar populates with a list of recommendations or a day-by-day itinerary. The right side of the screen is a map with all the pinned recommendations for easy navigating.

For those wanting to travel more within Texas this summer, Airheart offers a few destinations with a wide range of activities:

  • Big Bend/West Texas: For nature lovers, explore the beautiful mountain desert region of West Texas with a comprehensive guide that includes tips on how to get there and how to choose the best accommodation for your trip — something that becomes more complex in such a remote place.
  • Glen Rose: Escape to this charming small town just an hour-and-a-half Southwest of Dallas-Fort Worth, that is perfect for a weekend getaway full of outdoor adventures. These recommendations come from a local.
  • Fredericksburg: Indulge in the best wineries and restaurants that Central Texas has to offer with an itinerary crafted by a Texas native. This one is ideal for a quick day trip or a fun girls’ weekend.

Airheart, named after the pioneering aviator Amelia Earhart, is also focused on empowering female travel creators by allowing them to act as a type of modern travel agent. They can monetize both new and existing travel content by creating these guides and itineraries, while reaching a new audience on the platform.

“As an avid traveler, I’m always looking for something like this created by expert travelers. I can’t wait to be a seller and consumer,” said Tanna Wasilchak who contributed guides for Waco, Glen Rose, and Georgetown. “Solo traveling as a female can be intimidating at first, but it’s one of the most rewarding experiences I’ve ever had. Airheart is going to be such a game changer for this community.”

Perhaps the only downside for now is that Airheart is limited in what it can offer to its users with only 22 guides published on the site. However, the features and community-based aspect give the platform the potential to stand out in an otherwise saturated market. Guides ($29 each before taxes and fees) are available for users to browse and purchase at airheart.com.

------

This article originally ran on CultureMap.

Houston startup adviser on navigating SAFE, convertible notes in funding rounds

guest column

As both a founder and occasional early-stage investor in the Houston ecosystem, I've seen firsthand the opportunities and challenges surrounding seed funding for local startups. This critical first fundraising round sets the trajectory, but navigating the landscape can be tricky, especially for first time founders who may not be familiar with the lingo.

One key dynamic is choosing the right deal structure — SAFEs (Simple Agreement for Future Equity) vs. convertible notes are the most common vehicles early stage startups use to raise capital and are far more founder-friendly than a priced round.

Let's start first with what the have in common:

  • Both allow you to defer setting a valuation for your company until a later (likely priced) round, which is useful in early stages or pre-revenue companies
  • Both are cheaper and faster to execute than a priced round, which cash-strapped early stage founders like
  • Both can have terms like valuation cap, discount, conversion event, and pro rata rights.
  • Both are less attractive to investors seeking immediate equity (especially important if starting the QSBS clock is part of your investors strategy or if the investor is newer to startup investing)
  • Both can create messy cap tables and the potential for a lot of dilution for the founders (and investors) if they are used for multiple raises (especially with different terms)

While as you can see they have similarities, they have some important differences. Let's dig in on these next:

SAFEs:

  • Created by Y Combinator in 2013, the intent was to create a simplified, founder friendly agreement as an alternative to the convertible note
  • Is an agreement for future equity for the investor at a conversion event (priced round or liquidation event) which converts automatically.
  • It's not a debt instrument and does not accrue interest or have a maturity date.
  • Generally have much lower upfront legal costs and faster to execute

Convertible Notes:

  • A debt agreement that converts to equity at a later date (or conversion event like a priced round)
  • Accrues interest (usually 2 to 8 percent) and has a maturity date by which the note must either be repaid or convert to equity. If you reach your maturity date before raising a qualifying round, you can often renegotiate to extend the maturity date or convert the note, though be prepared to agree to higher interest rates, additional warrants, or more favorable conversion terms.
  • More complex and take longer to finalize due to non-standard terms resulting in higher legal and administrative costs

It's worth reiterating that in both cases, raising multiple rounds can lead to headaches in the form of complex cap tables, lots of dilution, and higher legal expenses to determine conversion terms. If your rounds have different terms on discounts and valuation caps (likely) it can cause confusion around equity and cap table structure, and leave you (the founder) not sure how much equity you will have until the conversion occurs.

In my last startup, our legal counsel — one of the big dogs in this space for what it's worth — strongly advised us to only do one SAFE round to prevent this.

Why do some investors tend to prefer convertible notes?

There are a few reasons why some investors, particularly angel investors from developing startup ecosystems (like Houston), prefer convertible notes to SAFEs.

  • Because they are structured as debt, note holders have a higher priority than equity investors in recovering their investment if the company fails or is liquidated. This means they would get paid after other creditors (like loans or credit cards) but before equity investors, increasing the likelihood of getting some of their money back.
  • The interest terms protect investors if the founder takes a long time to raise a priced funding round. As time passes, interest accumulates, increasing the investor's potential return. This usually results in the investor receiving a larger equity stake when the note converts. However, if the investor chooses to call in the note instead, the accrued interest would increase the amount of money owed, similar to a traditional loan
  • More defined conversion triggers (including a maturity date) gives investors more control and transparency on when and how their investment will convert.
  • Can negotiate more favorable terms than the standard SAFE agreement, including having both a valuation cap and a discount (uncommon on a SAFE, which usually only has one or the other), interest rates, and amendment clauses to protect them from term revisions on earlier investors by future investors (called a cram-down), etc.
We'll go over what the various terms in these agreements are and what to look out for in a future article

How to choose:

  • Consider your startup's stage and valuation certainty — really uncertain or super early? Either of these instruments are preferable to a priced round as you can defer the valuation discussion
  • Assess investor preferences in your network — often the deciding factor if you don't have a lot of leverage; most local angels prefer c-notes because they see them as less risky though SAFEs are becoming more common with investors in tech hubs like Silicon Valley
  • Evaluate your timeline and budget for legal costs — as I mentioned, SAFEs are way less expensive to execute (though still be prepared to spend some cash).
  • Align the vehicle with your specific goals and growth trajectory

There's no one-size-fits-all solution, so it's crucial to weigh these factors carefully.

The meanings of these round terms like "seed" are flexible, and the average seed funding amount has increased significantly over the past decade, reaching $3.5 million as of January 2024. This trend underscores the importance of choosing the right funding vehicle and approach.

Looking ahead, I'm bullish on Houston's growing startup ecosystem flourishing further. Expect more capital formation from recycled wins, especially once recently minted unicorns like High Radius, Cart.com, Solugen, and Axiom Space exit and infuse the ecosystem with fresh and hungry angels, new platforms beyond traditional venture models, and evolving founder demographics bringing fresh perspectives.

------

Adrianne Stone is the principal product manager at Big Cartel and the founder of Bayou City Startups, a monthly happy hour organizer. This article original ran on LinkedIn.

Innovative Houston nonprofit partners with county organization to provide maternal health services

TEAM WORK

PUSH Birth Partners, a Houston-based maternal health nonprofit, is teaming up with the Harris County Public Health Department to provide doula services for over 200 pregnant people free of cost.

Jacqueline McLeeland, CEO and founder of PUSH, says the program will begin in August and aims to improve maternal health and birth outcomes for vulnerable populations. McLeeland says the organization has built up a strong doula training program through their collective in partnership with March of Dimes and several local doula organizations.

McLeeland says PUSH aims to address poor maternal health outcomes for women of color in part by training more doulas of color who can help reduce racial disparities in care. A 2021 study by Harris County Public Health found Precinct 1, which is predominantly composed of people of color, had the highest maternal mortality rate of the county.

Through their collective, PUSH has trained two cohorts of doulas through an integrated care model, focused on providing collaborative care with medical providers in the healthcare system.

“Our programs are designed to advance health equity, we see the numbers, we see that women of color, specifically Black women in that group are disproportionately impacted,” McLeeland tells InnovationMap.

After receiving a $100,000 grant from the Episcopal Health Foundation in 2023, PUSH began their doula expansion program in Houston and they have since received an additional grant from EHF for the next fiscal year. McLeeland shares PUSH has also launched a pilot program called Blossoming Beyond Birth, sponsored by the Rockwell Fund, targeted towards improving maternal mental health through weekly support groups in Houston.

“It’s very exciting to know that we have come this far from where we started and to see how everything is coming together,” McLeeland shares.

Jacqueline McLeeland serves as chief executive and founder of non-profit PUSH Birth Partners who has trained and collaborated with a network of doulas for the partnership. Photo courtesy of Jacqueline McLeeland

For McLeeland, improving maternal health outcomes and providing support to people experiencing high-risk pregnancies are deeply personal goals. McLeeland has sickle cell anemia, a condition that can cause serious complications during pregnancy. During her first pregnancy in 2015, McLeeland was placed on bed rest two months before her due date at which point she had been working in clinical research within the pharmaceutical industry for over 12 years.

“People don’t realize the magnitude of what women go through, during pregnancy and after,” McLeeland says. “There’s a lot of emotional, psychological, and physical tolls depending on how the pregnancy and delivery went.”

After giving birth to her first child, McLeeland took maternity leave, during which she began to research maternal morbidity and mortality trends, information which she says was not widely discussed at the time.

McLeeland says entering the maternal healthcare field felt like a necessity following her second pregnancy. Several months after giving birth to her second child, McLeeland says she received a bill for a surgical procedure that was performed during her cesarean section without her or her husband’s consent. McLeeland says that was the first time she was made aware of the surgery.

“The procedure that was claimed to have been performed could have put my life in jeopardy by hemorrhaging based off of additional research I did once, I came across that information,” McLeeland explains. “These are some of the things that happen in the healthcare system that make people skeptical of trusting in the healthcare system, trusting in doctors.”

McLeeland says the key to improving maternal and birth outcomes for vulnerable populations is to encourage the partnership between doulas, community healthcare workers, and physicians and hopes to further this collaboration through future programming.